Alfresa Holdings Corporation (ALFRY) Aktienanalyse
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Mit einem Kurs von $ ist Alfresa Holdings Corporation (ALFRY) ein Healthcare-Unternehmen mit einer Bewertung von 0. Bewertet mit 49/100 (vorsichtig) bei Wachstumspotenzial, finanzieller Gesundheit und Momentum.
Zuletzt analysiert: 16. März 2026Alfresa Holdings Corporation (ALFRY) Gesundheitswesen & Pipeline-Uebersicht
Alfresa Holdings Corporation, a Japanese healthcare conglomerate, manufactures, wholesales, and distributes pharmaceuticals, diagnostic reagents, and medical devices. With a focus on ethical pharmaceuticals and self-medication products, the company serves hospitals, clinics, and pharmacies in Japan and internationally, maintaining a stable position in the medical distribution landscape.
Investmentthese
Alfresa Holdings Corporation presents a stable investment profile within the healthcare distribution sector. The company's diversified revenue streams, spanning ethical pharmaceuticals, self-medication products, and manufacturing, provide resilience against market fluctuations. With a P/E ratio of 12.91 and a dividend yield of 2.76% as of 2026-03-16, Alfresa offers a blend of value and income potential. The company's low beta of -0.16 suggests a lower sensitivity to market volatility compared to its peers. Growth catalysts include expanding its self-medication product lines and penetrating new international markets. Potential risks include regulatory changes in the pharmaceutical industry and increased competition from other distributors.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- Market capitalization of $2.91 billion indicates a substantial presence in the healthcare sector.
- P/E ratio of 12.91 suggests a reasonable valuation compared to earnings.
- Dividend yield of 2.76% provides a steady income stream for investors.
- Gross margin of 7.1% reflects the company's ability to manage its cost of goods sold.
- Profit margin of 1.1% indicates areas for potential improvement in operational efficiency.
Wettbewerber & Vergleichsunternehmen
Staerken
- Diversified revenue streams across wholesale, manufacturing, and pharmacy operations.
- Established distribution network in Japan.
- Strong relationships with key customers, including hospitals and pharmacies.
- Manufacturing capabilities for active pharmaceutical ingredients and finished drugs.
Schwaechen
- Relatively low profit margin compared to industry peers.
- Dependence on the Japanese market.
- Exposure to regulatory changes in the pharmaceutical industry.
- Limited international presence compared to global competitors.
Katalysatoren
- Ongoing: Expansion of self-medication product lines to meet growing consumer demand for OTC drugs and health supplements.
- Ongoing: Strategic partnerships to enhance distribution network and market reach in key regions.
- Upcoming: Potential regulatory approvals for new pharmaceutical products, expanding the company's product portfolio.
- Ongoing: Investment in digital distribution channels to capitalize on the growth of e-pharmacy market.
- Ongoing: Development of value-added services to enhance customer loyalty and generate recurring revenue.
Risiken
- Potential: Increased competition from other pharmaceutical distributors, leading to pricing pressures.
- Potential: Changes in government regulations and healthcare policies, affecting reimbursement rates and market access.
- Potential: Economic downturns affecting healthcare spending and consumer demand for pharmaceuticals.
- Ongoing: Currency fluctuations between the U.S. dollar and the Japanese yen, impacting the value of the ADR.
- Potential: Product liability claims or recalls, damaging the company's reputation and financial performance.
Wachstumschancen
- Expanding Self-Medication Product Lines: Alfresa can capitalize on the growing demand for over-the-counter drugs and health supplements. The global self-medication market is projected to reach $200 billion by 2028. By introducing innovative products and expanding its distribution network, Alfresa can increase its market share in this segment. Timeline: Ongoing.
- Penetrating New International Markets: Alfresa has the opportunity to expand its presence in emerging markets with growing healthcare needs. The Asia-Pacific region, in particular, offers significant growth potential. By establishing partnerships and adapting its product offerings to local market demands, Alfresa can diversify its revenue streams. Timeline: 2-3 years.
- Enhancing Contract Manufacturing Services: Alfresa can leverage its manufacturing capabilities to offer contract manufacturing services to other pharmaceutical companies. The global pharmaceutical contract manufacturing market is expected to reach $150 billion by 2027. By investing in advanced manufacturing technologies and expanding its capacity, Alfresa can attract new clients and generate additional revenue. Timeline: Ongoing.
- Strengthening Digital Distribution Channels: Alfresa can enhance its online presence and develop digital distribution channels to reach a wider customer base. The e-pharmacy market is experiencing rapid growth, driven by increasing internet penetration and changing consumer preferences. By investing in e-commerce platforms and digital marketing strategies, Alfresa can capture a share of this growing market. Timeline: 1-2 years.
- Developing Value-Added Services: Alfresa can differentiate itself from competitors by offering value-added services to its customers, such as inventory management, supply chain optimization, and data analytics. These services can help hospitals, clinics, and pharmacies improve their operational efficiency and reduce costs. By providing customized solutions and building strong customer relationships, Alfresa can enhance customer loyalty and generate recurring revenue. Timeline: Ongoing.
Chancen
- Expanding self-medication product lines to capitalize on growing consumer demand.
- Penetrating new international markets, particularly in Asia-Pacific.
- Enhancing contract manufacturing services to generate additional revenue.
- Strengthening digital distribution channels to reach a wider customer base.
Risiken
- Increased competition from other pharmaceutical distributors.
- Pricing pressures from generic drugs.
- Changes in government regulations and healthcare policies.
- Economic downturns affecting healthcare spending.
Wettbewerbsvorteile
- Established distribution network in Japan.
- Diversified product portfolio spanning pharmaceuticals, diagnostics, and medical devices.
- Manufacturing capabilities for active pharmaceutical ingredients and finished drugs.
- Strong relationships with hospitals, clinics, and pharmacies.
Ueber ALFRY
Incorporated in 2003 and based in Tokyo, Japan, Alfresa Holdings Corporation has established itself as a key player in the healthcare sector. The company operates through its subsidiaries, engaging in the manufacture, wholesale, marketing, and import/export of a diverse range of healthcare products. These include pharmaceuticals, diagnostic reagents, and medical devices/equipment. Alfresa's operations are segmented into ethical pharmaceuticals wholesaling, self-medication products wholesaling, and manufacturing. The ethical pharmaceuticals division supplies hospitals, clinics, and dispensing pharmacies with essential products. The self-medication division caters to drug stores and pharmacies, offering over-the-counter drugs, health foods, and supplements. Alfresa also manufactures active pharmaceutical ingredients, pharmaceuticals, diagnostic reagents, and medical devices, providing contract manufacturing services. The company's medical-related business encompasses dispensing pharmacies and other healthcare activities, further solidifying its presence in the healthcare value chain. Alfresa's international reach extends its market presence beyond Japan, contributing to its revenue streams and overall growth.
Was das Unternehmen tut
- Wholesales ethical pharmaceuticals to hospitals, clinics, and dispensing pharmacies.
- Distributes self-medication products, including OTC drugs and health supplements, to drug stores and pharmacies.
- Manufactures active pharmaceutical ingredients and pharmaceuticals.
- Produces diagnostic reagents and medical devices.
- Offers contract manufacturing services for pharmaceuticals.
- Operates dispensing pharmacies.
Geschaeftsmodell
- Revenue from wholesale distribution of pharmaceuticals and medical products.
- Income from manufacturing and sales of active pharmaceutical ingredients and finished drugs.
- Fees from contract manufacturing services.
- Revenue generated from operation of dispensing pharmacies.
Branchenkontext
Alfresa Holdings Corporation operates within the medical distribution industry, a sector characterized by steady growth driven by aging populations and increasing healthcare expenditure. The industry is competitive, with players like CHSYF, DMPHF, HAWPF, HTSUF, and MAHLY vying for market share. Trends include consolidation among distributors and increased focus on supply chain efficiency. Alfresa's diversified product portfolio and established distribution network position it favorably within this landscape.
Wichtige Kunden
- Hospitals and clinics.
- Dispensing pharmacies.
- Drug stores.
- Other pharmaceutical companies (for contract manufacturing).
Finanzdaten
Chart & Info
Alfresa Holdings Corporation (ALFRY) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
Keine aktuellen Nachrichten fuer ALFRY verfuegbar.
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer ALFRY.
Kursziele
Wall-Street-Kurszielanalyse fuer ALFRY.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von ALFRY auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
Fuehrung: Ryuji Arakawa
Unknown
Information regarding Ryuji Arakawa's specific background and career history is not available in the provided data. However, as the managing leader of Alfresa Holdings Corporation's 12,517 employees, Arakawa likely possesses extensive experience in the pharmaceutical or healthcare distribution industry. Further research would be needed to ascertain specific details about his education, previous roles, and credentials.
Erfolgsbilanz: Due to the limited information available, Ryuji Arakawa's specific achievements and strategic decisions as CEO of Alfresa Holdings Corporation cannot be detailed. Evaluating his track record would require access to company performance data, strategic initiatives, and key milestones achieved under his leadership.
Alfresa Holdings Corporation ADR-Informationen Nicht gesponsert
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company that trades on U.S. stock exchanges. ALFRY is an ADR representing shares of Alfresa Holdings Corporation, allowing U.S. investors to invest in the Japanese company without directly dealing with foreign exchanges. The ADR is denominated in U.S. dollars, simplifying trading and investment for U.S. investors.
- Heimatmarkt-Ticker: Tokyo Stock Exchange, Japan
- ADR-Stufe: 1
- ADR-Verhaeltnis: 1:1
- Heimatmarkt-Ticker: ALFR
ALFRY OTC-Marktinformationen
The OTC Other tier represents the lowest tier of the over-the-counter (OTC) market. Companies in this tier often have limited financial disclosure and may not meet the listing requirements of major exchanges like the NYSE or NASDAQ. Investing in OTC Other stocks carries higher risks due to the lack of regulatory oversight and potential for fraud or manipulation. These companies are not required to be SEC reporting.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
- Limited financial disclosure increases the risk of investing in ALFRY.
- Low trading volume and wide bid-ask spreads can lead to price volatility and illiquidity.
- Lack of regulatory oversight increases the risk of fraud or manipulation.
- Potential for delisting or suspension of trading.
- Difficulty obtaining accurate and timely information about the company.
- Verify the company's registration and legal status.
- Obtain and review any available financial statements.
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's risk factors and potential liabilities.
- Consult with a qualified financial advisor.
- Understand the OTC market and its associated risks.
- The company is an established player in the healthcare sector.
- Alfresa Holdings Corporation is based in Japan, a country with strong corporate governance standards.
- The company has a long operating history.
- ALFRY is an ADR, suggesting some level of scrutiny and compliance.
- The company has a market capitalization of $2.91 billion, indicating a substantial business.
ALFRY Healthcare Aktien-FAQ
What are the key factors to evaluate for ALFRY?
Alfresa Holdings Corporation (ALFRY) currently holds an AI score of 49/100, indicating low score. Key strength: Diversified revenue streams across wholesale, manufacturing, and pharmacy operations.. Primary risk to monitor: Potential: Increased competition from other pharmaceutical distributors, leading to pricing pressures.. This is not financial advice.
How frequently does ALFRY data refresh on this page?
ALFRY prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven ALFRY's recent stock price performance?
Recent price movement in Alfresa Holdings Corporation (ALFRY) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Diversified revenue streams across wholesale, manufacturing, and pharmacy operations.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider ALFRY overvalued or undervalued right now?
Determining whether Alfresa Holdings Corporation (ALFRY) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying ALFRY?
Before investing in Alfresa Holdings Corporation (ALFRY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding ALFRY to a portfolio?
Potential reasons to consider Alfresa Holdings Corporation (ALFRY) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Diversified revenue streams across wholesale, manufacturing, and pharmacy operations.. Additionally: Established distribution network in Japan.. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of ALFRY?
Yes, most major brokerages offer fractional shares of Alfresa Holdings Corporation (ALFRY) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track ALFRY's earnings and financial reports?
Alfresa Holdings Corporation (ALFRY) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for ALFRY earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- Information is based on available data as of 2026-03-16.
- Analyst consensus and detailed CEO background information are limited.
- OTC market data may be less reliable than exchange-listed data.